

SAIL Capital Partners Announces Unprecedented Results from CNS Response's Bioinformatics Breakthrough

Irvine, CA- (Aug.18, 2011) – [SAIL Capital Partners](#) has announced that its portfolio company [CNS Response, Inc.](#) (OTCBB: [CNSO](#)), has achieved top line results from an analysis of physician reports and health records released by a high-volume managed care psychiatric clinic which services several of the nation's largest managed care networks.

The initial analysis of 128 records of patients treated for mental health conditions from 2003 to mid-2011 represents cases in which physicians received CNS Response's PEER Outcome Reports™ for their patients. The analysis found that physicians who had access to PEER Outcomes reported a reduction in the number of medications that had to be tried on a patient before achieving a successful outcome, otherwise known as trial-and-error pharmacotherapy.

Among the findings of the analysis:

- 16 patients, or 13%, actually required no medications at all.

Of the remaining 112 patients who required medications, when their physicians had access to the PEER Outcome Report:

- 88% of the patients achieved "much improved" or "very much improved" health outcomes.

In addition to the initial payer analysis, CNS Response announced that a detailed technology assessment of CNS Response's Referenced-EEG® (rEEG®), the company's original physician-developed database, was recently completed by [OptumHealth](#). A unit of [UnitedHealthcare](#), OptumHealth approved rEEG as an "Emerging Technology." The Technology Assessment is now available online to registered United/OptumHealth network providers, and will be posted to www.ubhonline.com/html/clinResources.html on August 26. It will also be available in the physician section of the CNS Response website.

Since January 1, 2010, the company has also received 313 physician rating reports, with 94 percent of physicians indicating the information provided through the CNS Response PEER Outcome Report was "helpful" and 47 percent indicating the information was "essential" in treating their patients.

"These results were achieved by physicians, not a report," said **George Carpenter, CNS Response CEO**. "It's a basic principle of medicine that physicians who exchange outcome information achieve better -- sometimes dramatically better -- results than those who don't.

CNS Response is backed by private investment firm, SAIL Capital Partners. **Alan Sellers, Senior Partner with SAIL Capital Partners**, noted, "CNS Response was an early SAIL investment where we were experimenting at the horizon of defining a medical version of cleantech. We are pleased that our faith in this efficient path-breaking technology has been rewarded by medical system adoption."

-###-

About CNS Response

CNS Response provides reference data and analytic tools for clinicians and researchers in psychiatry.

While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorder. The company recently launched the Psychiatric EEG Evaluation Registry, or PEER Online™, a new registry and cloud-based reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through an EEG. PEER Online builds on the company's original physician-developed database, Referenced-EEG® (rEEG®). Avoiding trial and error pharmacotherapy, the dominant approach for psychiatric treatment, is the objective of PEER Online™.

To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.cnsresponse.com. Medical professionals interested in learning more can contact CNS Response at PEERinfo@cnsresponse.com.

ABOUT SAIL

SAIL Capital Partners (www.sailcapital.com) is a cleantech investment firm with unique global insight into technologies, markets and opportunities. Drawing on decades of experience in cleantech and in growing successful businesses, the SAIL team invests in companies with proven technologies, visionary leadership, demonstrated revenue and profit growth potential. SAIL has invested in a number of the world's leading cleantech companies, including: FlexEnergy, The Cleantech Group, Xtreme Power, Enerpulse, Kokam Advanced Batteries, M2 Renewables and WaterHealth International.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.